Skip to content
Menu

RBC Capital Maintains Outperform on BeOne Medicines, Raises Price Target to $465

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and raises the price target from $459 to $465.

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and raises the price target from $459 to $465.

Read at benzinga.com